N/A N=101 Short Implants - An Alternative to Bone Grafting?
Jaw, Edentulous, Partially
Primary: Implant Survival Rate — 66; 70 Implants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 Efficacy of Preoperative Autologous Blood Donation and Tranexamic Acid in Revision Total Hip Arthroplasty
Revision Total Hip Arthroplasty (RTHA)
Primary: Number of Transfused Allogeneic Blood Units (in Digits). — 2.0; 0.0 units
Phase 1 N=24 A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
Alzheimer's Disease
Primary: Test-Retest Reproducibility — 1.342; 1.355 standardized uptake value ratio (SUVr)
Phase 4 N=63 The OBstetric Lidocaine Patch (OBLido) Trial
Pain, Postoperative
Primary: Total Dose of Opioids Received in the First 24 Hours Following Cesarean — 87; 83.9 MME, morphine milligram equivalents
Phase 3 N=156 18F-AV-1451 Autopsy Study
Alzheimer's Disease
Primary: Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score) — 97.4; 68.0; 92.3; 92.0 percentage of cases correctly identified
Phase 4 N=3,092 INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
Pulmonary Disease, Chronic Obstructive
Primary: Number of Responders and Non-responders Based on the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 24 and Number of Participants With Imputed CAT…
N/A N=117 SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)
Substance Use Disorders · Posttraumatic Stress Disorder
Primary: Severity of Alcohol Use (ASI Alcohol Composite Scores) — .259; .225; .169; .152 units on a scale — p=> .05
Phase 1 N=15 A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Solid Tumor
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Entrectinib — 41500; 46600; 43400; 9860 nmol*h/L
N/A N=20 Respiratory Muscle Strength Training in Presbyphonia
Presbylarynx
Primary: Post-Treatment Mean in Voice Handicap Index Score — 15.00; 15.75; 18.50 score on a scale — p=0.041
Phase 3 N=552 Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score — -22.90; -23.28; -22.64; -24.37 score on a scale — p=0.8035
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 3 N=167 Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs) — 133 Participants
Phase 2 N=41 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959
Phase 3 N=373 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale — -3.10; -3.49; -2.80 units on a scale
Phase 3 N=117 Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Chronic HCV Infection
Primary: Evaluation of the Efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve as Measured by the Proportion of Subjects With Sustained…